What’s Really in Your Water: Pharmaceutical and Drug Residues, Wastewater-Based Epidemiology, and How Treatment Removes Them

In short: Trace amounts of pharmaceuticals and illicit drug metabolites are routinely detected in municipal wastewater and, at far lower concentrations, in finished drinking water. A 2025 study of 97 pharmaceuticals found roughly 40% of tested compounds present in wastewater at levels up to 12,664 ng/L. Public health agencies now use that same wastewater to track community drug use in near real time, a method called wastewater-based epidemiology. And full-scale treatment data shows reverse osmosis removing 92.6% to 99.9% of tested pharmaceuticals, with granular activated carbon picking up much of what remains. The compounds are real. So is the technology already removing them.

This isn’t a fringe topic anymore. In April 2026, the EPA published a draft Sixth Contaminant Candidate List that, for the first time, names pharmaceuticals as a contaminant group for potential future drinking water regulation, alongside human health benchmarks covering 374 individual pharmaceutical compounds. That’s a formal signal from a federal regulator that this issue has moved from academic curiosity to something water systems need to plan around.

What Pharmaceuticals and Drugs Actually Show Up in Wastewater?

Nearly everything that gets metabolized by the human body ends up, in some form, going down the drain, whether through excretion, unused medication flushed down a toilet, or residue washed off skin. Researchers testing 97 different pharmaceuticals in wastewater treatment plant influent and effluent found roughly 40% of them detectable, at concentrations ranging from below the detection limit up to 12,664 nanograms per liter in wastewater and 5,623 ng/L in the surface water receiving it, according to a 2025 peer-reviewed occurrence study.

The list runs wide: antibiotics like amoxicillin and ampicillin, antidepressants such as venlafaxine and fluoxetine, the diabetes drug metformin (one of the most consistently detected pharmaceuticals in wastewater globally because of how little the body metabolizes it), anticonvulsants like carbamazepine, and everyday stimulants like caffeine. On the illicit side, wastewater consistently carries metabolites of methamphetamine, cocaine, cannabis, and opioids, along with the drugs used to treat opioid use disorder, like methadone.

None of this means tap water is unsafe. USGS and state-level testing consistently finds pharmaceuticals in finished drinking water at parts-per-trillion concentrations, thousands of times below levels associated with any therapeutic or toxicological effect. A 2025 study across Minnesota drinking water systems found pharmaceuticals in less than 1% of samples, with detected concentrations between 0.502 and 86.2 ng/L. The presence of a compound at trace levels is not the same as a health risk. But the fact that these compounds get through conventional treatment at all is exactly why more utilities and industrial facilities are looking at advanced treatment as something other than optional.

Why Do These Compounds End Up in Water in the First Place?

Conventional wastewater treatment, the biological and settling processes most municipal plants run, was never engineered to target pharmaceutical compounds. It was built to handle organic waste, solids, and pathogens. Pharmaceuticals are small, often water-soluble molecules designed specifically to resist breakdown long enough to work in the human body, which is exactly what makes many of them resistant to standard treatment too.

Research comparing treatment stages backs this up directly: conventional plants show very limited efficiency removing organic micropollutants like antibiotics, while advanced technologies, ozonation, advanced oxidation, and activated carbon, perform substantially better. That gap between what conventional treatment removes and what modern analytical chemistry can detect is the whole reason this conversation exists. We didn’t get better at making dirty water. We got better at finding out how clean it actually is.

What Is Wastewater-Based Epidemiology, and Why Are Public Health Agencies Using It?

Wastewater-based epidemiology is the practice of testing sewage for drug metabolites to estimate real-time community drug use, without needing individual surveys or self-reported data. It works because a population’s collective urine and waste stream carries a chemical signature of what’s actually being consumed, not what people say they’re consuming.

The scale of this in the U.S. is bigger than most people realize. The White House Office of National Drug Control Policy runs a wastewater-based drug epidemiology program spanning more than 100 counties, covering roughly 18% of the U.S. population, according to an ONDCP wastewater newsletter published in mid-2026. The program quantitatively measures more than 20 drugs and screens for the presence of over 500 substances, making it the largest wastewater drug-monitoring effort in the country. It’s used to spot emerging drug trends, like a new synthetic opioid showing up in a specific region, faster than hospital admission data or overdose reports would reveal it.

Europe runs a parallel effort. The European Union Drugs Agency’s 2025 monitoring campaign involved 19 countries testing wastewater across multiple cities each, and researchers in Guangdong Province, China sampled 67 wastewater treatment plants across four cities between 2023 and 2024, finding methamphetamine the most consumed drug regionally, at 65 to 223 milligrams per 1,000 inhabitants per day. The method has also been applied inside prison systems, where a 2025 review found cocaine, cannabis, methamphetamine, and methadone as the most commonly monitored substances.

For water treatment operators, this matters beyond public health tracking. The same influent sampling infrastructure used for epidemiology often overlaps with the monitoring points utilities already use to characterize what’s entering their plant, which means the data feeds back into treatment planning too.

Can Reverse Osmosis Actually Remove Pharmaceutical and Drug Residues?

Yes, and the removal rates are high. Full-scale facility testing has shown reverse osmosis removing between 92.6% and 99.9% of a range of tested pharmaceuticals, including metformin, trimethoprim, caffeine, venlafaxine, carbamazepine, erythromycin, and fluoxetine. RO works on these compounds the same way it works on salts and other dissolved solids: the semipermeable membrane physically excludes molecules above a certain size and charge, and most pharmaceutical compounds are large enough, and polar enough, to be rejected at a high rate.

Studies focused specifically on antibiotics found similarly strong performance, with rejection rates ranging from about 73.5% to 99.4% for amoxicillin and 75.1% to 98.8% for ampicillin, depending on membrane type and operating conditions. That range matters. RO isn’t a single fixed number, it’s a system that performs differently depending on membrane selection, pressure, feed water chemistry, and how the system is configured. This is exactly why generic consumer filtration and properly engineered industrial or municipal-scale RO produce very different results in practice.

AMPAC USA designs industrial reverse osmosis systems built around that reality, configured for the actual feed water and contaminant profile a facility is dealing with, not a one-size-fits-all cartridge. For facilities handling wastewater with a known pharmaceutical or organic micropollutant load, that engineering step is the difference between a system that technically runs and one that actually hits the removal targets a plant needs.

Where Does Activated Carbon Fit In, and Why Pair It With RO?

Activated carbon catches what reverse osmosis membranes don’t fully reject, and it does it through a completely different mechanism: adsorption, where organic molecules bind to the enormous internal surface area of the carbon rather than being physically blocked by a membrane. Granular activated carbon (GAC) has been shown to be highly effective at simultaneously removing dissolved organic carbon and micro-organic pollutants from reverse osmosis concentrate, the waste stream left over after RO treatment.

That pairing, RO followed by GAC, is a well-established combination in advanced water treatment specifically because the two technologies cover each other’s gaps. RO handles the bulk removal of dissolved compounds at high rejection rates. Activated carbon polishes the water further and treats the concentrate stream, catching smaller or less-polar compounds that can pass through membrane pores more easily. Research on river bank filtrate treatment found that RO followed by activated carbon filtration efficiently removed organic micropollutants where either technology alone left measurable residue.

For a facility looking at commercial reverse osmosis systems or evaluating a broader wastewater reuse strategy, this two-stage approach is generally where the real performance gains show up, not from over-specifying one technology, but from combining membrane separation with adsorption to close the gap that conventional treatment alone can’t close.

What Does This Mean for Facilities and Water Systems Right Now?

The EPA’s April 2026 draft Contaminant Candidate List, with human health benchmarks now published for 374 pharmaceuticals, is a clear signal that pharmaceutical residues are moving toward formal regulatory attention, not staying an academic footnote. EPA plans to finalize the list by November 17, 2026. Facilities that treat wastewater with any pharmaceutical, hospital, senior-care, or high-population residential load have a real reason to look at their current treatment capability now, before a regulatory deadline forces the question.

This is also not purely a compliance story. Facilities that reuse treated water, for irrigation, cooling, or process water, are increasingly expected to demonstrate that reuse water meets a higher bar than “passed conventional treatment.” Reverse osmosis systems engineered for the actual contaminant profile of a facility’s wastewater, not a generic assumption, are the practical way to meet that bar today, ahead of whatever the EPA’s list becomes in November.

Frequently Asked Questions

Is it dangerous to drink tap water with trace pharmaceuticals in it?

Detected concentrations in finished drinking water are typically in the parts-per-trillion range, thousands of times below any level associated with a therapeutic or toxicological effect. A 2025 Minnesota study found pharmaceuticals in less than 1% of drinking water samples tested, at concentrations between 0.502 and 86.2 ng/L. Presence at trace levels is not the same thing as a health risk, but it’s also why utilities and industrial facilities are increasingly adopting advanced treatment rather than relying on detection thresholds alone.

What is wastewater-based epidemiology and is my city’s sewage being tested?

It’s the practice of testing municipal wastewater for drug metabolites to track community-level drug use in near real time. In the U.S., the ONDCP’s program covers more than 100 counties and roughly 18% of the population as of 2026, so it’s likely your region participates or has comparable state-level monitoring in place.

Can standard municipal wastewater treatment remove pharmaceuticals?

Not reliably. Conventional biological wastewater treatment was designed for organic waste and pathogens, not small, chemically stable pharmaceutical molecules, and research shows it has limited efficiency against compounds like antibiotics. Advanced treatment, reverse osmosis, activated carbon, ozonation, and advanced oxidation processes, is what actually closes that gap.

How effective is reverse osmosis specifically at removing drug residues?

Full-scale facility data shows RO removing 92.6% to 99.9% of a range of tested pharmaceuticals, with antibiotic-specific studies showing rejection rates from roughly 73.5% to 99.4% depending on the compound and membrane configuration. Properly engineered industrial RO systems, matched to the facility’s actual feed water, consistently perform at the high end of that range.

Why pair reverse osmosis with activated carbon instead of using one or the other?

RO and activated carbon remove contaminants through different mechanisms, membrane rejection versus adsorption, so pairing them closes gaps that either technology leaves alone. Studies on RO concentrate and river bank filtrate both found the combination removed organic micropollutants more completely than either method used by itself.

Sources: EPA Draft Sixth Contaminant Candidate List; EPA Human Health Benchmarks for Pharmaceuticals, 2026 Technical Document; Occurrence of 97 Pharmaceuticals in Wastewater and Receiving Waters, PMC; ONDCP Wastewater-Based Drug Epidemiology Newsletter; Wastewater-Based Epidemiology in Guangdong, China, PMC; EUDA Wastewater Analysis Multi-City Study; Removal of Trace Organic Contaminants by RO and GAC, PMC; Performance Evaluation of RO for Antibiotics Removal, PMC; GAC Removal from RO Concentrate, ScienceDirect.